These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Development of a cAdVax-based bivalent ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus. Wang D; Raja NU; Trubey CM; Juompan LY; Luo M; Woraratanadharm J; Deitz SB; Yu H; Swain BM; Moore KM; Pratt WD; Hart MK; Dong JY J Virol; 2006 Mar; 80(6):2738-46. PubMed ID: 16501083 [TBL] [Abstract][Full Text] [Related]
9. Vaccine potential of Ebola virus VP24, VP30, VP35, and VP40 proteins. Wilson JA; Bray M; Bakken R; Hart MK Virology; 2001 Aug; 286(2):384-90. PubMed ID: 11485406 [TBL] [Abstract][Full Text] [Related]
10. Insights into Ebola Virus VP35 and VP24 Interferon Inhibitory Functions and their Initial Exploitation as Drug Targets. Fanunza E; Frau A; Corona A; Tramontano E Infect Disord Drug Targets; 2019; 19(4):362-374. PubMed ID: 30468131 [TBL] [Abstract][Full Text] [Related]
11. VP24 is a molecular determinant of Ebola virus virulence in guinea pigs. Mateo M; Carbonnelle C; Reynard O; Kolesnikova L; Nemirov K; Page A; Volchkova VA; Volchkov VE J Infect Dis; 2011 Nov; 204 Suppl 3():S1011-20. PubMed ID: 21987737 [TBL] [Abstract][Full Text] [Related]
12. Ebola virus: new insights into disease aetiopathology and possible therapeutic interventions. Geisbert TW; Hensley LE Expert Rev Mol Med; 2004 Sep; 6(20):1-24. PubMed ID: 15383160 [TBL] [Abstract][Full Text] [Related]
13. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Geisbert TW; Lee AC; Robbins M; Geisbert JB; Honko AN; Sood V; Johnson JC; de Jong S; Tavakoli I; Judge A; Hensley LE; Maclachlan I Lancet; 2010 May; 375(9729):1896-905. PubMed ID: 20511019 [TBL] [Abstract][Full Text] [Related]
14. Evasion of interferon responses by Ebola and Marburg viruses. Basler CF; Amarasinghe GK J Interferon Cytokine Res; 2009 Sep; 29(9):511-20. PubMed ID: 19694547 [TBL] [Abstract][Full Text] [Related]
15. Successful treatment of ebola virus-infected cynomolgus macaques with monoclonal antibodies. Qiu X; Audet J; Wong G; Pillet S; Bello A; Cabral T; Strong JE; Plummer F; Corbett CR; Alimonti JB; Kobinger GP Sci Transl Med; 2012 Jun; 4(138):138ra81. PubMed ID: 22700957 [TBL] [Abstract][Full Text] [Related]
16. Discovery and early development of AVI-7537 and AVI-7288 for the treatment of Ebola virus and Marburg virus infections. Iversen PL; Warren TK; Wells JB; Garza NL; Mourich DV; Welch LS; Panchal RG; Bavari S Viruses; 2012 Nov; 4(11):2806-30. PubMed ID: 23202506 [TBL] [Abstract][Full Text] [Related]
17. Identification and Characterization of Defective Viral Genomes in Ebola Virus-Infected Rhesus Macaques. Johnson RI; Boczkowska B; Alfson K; Weary T; Menzie H; Delgado J; Rodriguez G; Carrion R; Griffiths A J Virol; 2021 Aug; 95(17):e0071421. PubMed ID: 34160256 [TBL] [Abstract][Full Text] [Related]
18. Pharmacotherapy of Ebola hemorrhagic fever: a brief review of current status and future perspectives. Olszanecki R; Gawlik G Folia Med Cracov; 2014; 54(3):67-77. PubMed ID: 25694097 [TBL] [Abstract][Full Text] [Related]
19. Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Oestereich L; Lüdtke A; Wurr S; Rieger T; Muñoz-Fontela C; Günther S Antiviral Res; 2014 May; 105():17-21. PubMed ID: 24583123 [TBL] [Abstract][Full Text] [Related]
20. Ebola virus VP35 perturbs type I interferon signaling to facilitate viral replication. Cao Z; Liu C; Peng C; Ran Y; Yao Y; Xiao G; Li E; Chen Z; Chuai X; Chiu S Virol Sin; 2023 Dec; 38(6):922-930. PubMed ID: 37839549 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]